Aspire Private Capital’s PharmaCyte Biotech PMCB Stock Holding History

Aspire Private Capital’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-800	Closed	-$1.53K	–	507
2024 Q3	$1.53K	Hold	800	–	–	﹤0.01%	567
2024 Q2	$1.57K	Hold	800	–	–	﹤0.01%	570
2024 Q1	$1.9K	Hold	800	–	–	﹤0.01%	585
2023 Q4	$1.73K	Hold	800	–	–	﹤0.01%	573
2023 Q3	$1.68K	Hold	800	–	–	﹤0.01%	575
2023 Q2	$2.29K	Hold	800	–	–	﹤0.01%	531
2023 Q1	$2.33K	Hold	800	–	–	﹤0.01%	526
2022 Q4	$2.34K	Hold	800	–	–	﹤0.01%	513
2022 Q3	$2K	Hold	800	–	–	﹤0.01%	524
2022 Q2	$2K	Hold	800	–	–	﹤0.01%	505
2022 Q1	$2K	Hold	800	–	–	﹤0.01%	510
2021 Q4	$2K	Buy	800 +400	+100%	+$1.1K	﹤0.01%	537
2021 Q3	$1K	Buy	+400	New	+$1.41K	﹤0.01%	562

Other funds holding PMCB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aspire Private Capital's PMCB Position: Q4 2024 in Review

Aspire Private Capital sold out of PharmaCyte Biotech (PMCB) in Q4 2024, closing a stake of 800 shares — an estimated $1.53K sold.

Aspire Private Capital first reported a position in PMCB in Q3 2021 and held it in 13 quarters. The position peaked at $2.34K in Q4 2022. 21 funds tracked by Wall St. Rank hold PMCB as of Q4 2024.

Aspire Private Capital reported no remaining PharmaCyte Biotech position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 800 PharmaCyte Biotech shares in Q4 2024, an estimated $1.53K.
Aspire Private Capital first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 13 quarters.
Aspire Private Capital's PharmaCyte Biotech position peaked at $2.34K in Q4 2022.
21 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.